Please assess the completion status of the following clinical trial:

Trial Title: Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Evidence of myeloma according to the criteria of the British Columbia Cancer Agency (for the diagnosis, 2 of the 3 criteria must be met):~  * Evidence of paraprotein in the serum or urine~ * Bone marrow infiltration with plasma cells which represent more than 10% of the nucleated cells~ * Radiologically, at least one osteolytic lesion~* Asymptomatic patients with Stage I (Durie and Salmon) multiple myeloma~Exclusion criteria:~* Patients with more than one osteolytic lesion on conventional skeletal radiography~* Previous treatment with bisphosphonates~* bilirubin \> 2.5 mg/dl~* Abnormal renal function as evidenced by: A calculated creatinine clearance \< 30 ml/minute. Creatinine clearance (CrCl) is calculated using the Cockcroft-Gault formula:~  * CrCl= \[140-age(years)\] x weight(kg)/\[72xserumcreatinine(mg/dL)\] X {0.85 for female patients}~* Patients with other malignant diseases or severe concomitant diseases~* Potentially fertile patients who are not using a reliable and appropriate method of contraception~* Pregnancy or breast-feeding~* Participation in another clinical study with an investigational drug within 12 weeks of study entry~* Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.~* Recent (within 6 weeks) or planned dental or jaw surgery (e.g.. extraction, implants)~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zoledronic acid (ZOL446) (Type: EXPERIMENTAL): Participants received intravenous infusion of Zoledronic acid every 4 weeks for 48 weeks, and calcium and Vitamin D daily.
- Control (Type: NO_INTERVENTION): No treatment with study medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).